Rain Oncology Inc. financial data

Industry
Pharmaceutical Preparations
Location
8000 Jarvis Avenue, Suite 204, Newark, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Rain Therapeutics Inc. (to 12/29/2022)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 563 % -35.5%
Debt-to-equity 21.5 % +64%
Return On Equity -83 % -24%
Return On Assets -68.3 % -15.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.4M shares +36.9%
Common Stock, Shares, Outstanding 36.4M shares +36.9%
Entity Public Float 43.9M USD -63.4%
Common Stock, Value, Issued 37K USD +37%
Weighted Average Number of Shares Outstanding, Basic 36.4M shares +36.9%
Weighted Average Number of Shares Outstanding, Diluted 36.4M shares +36.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 54.7M USD -4.03%
General and Administrative Expense 19.1M USD +30.1%
Operating Income (Loss) -76.6M USD -6.91%
Nonoperating Income (Expense) 4.35M USD +594%
Net Income (Loss) Attributable to Parent -72.3M USD -1.73%
Earnings Per Share, Basic -2.07 USD/shares +72.1%
Earnings Per Share, Diluted -2.07 USD/shares +72.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.3M USD -6.33%
Other Assets, Current 281K USD +243%
Assets, Current 80.8M USD -13.8%
Property, Plant and Equipment, Net 628K USD +510%
Operating Lease, Right-of-Use Asset 436K USD +49.8%
Other Assets, Noncurrent 180K USD -63.7%
Assets 82.1M USD -13.3%
Accounts Payable, Current 8.97M USD +120%
Liabilities, Current 14.5M USD +11.3%
Operating Lease, Liability, Noncurrent 39K USD -78.9%
Other Liabilities, Noncurrent 64K USD 0%
Liabilities 14.5M USD +9.94%
Accumulated Other Comprehensive Income (Loss), Net of Tax -64K USD +78.8%
Retained Earnings (Accumulated Deficit) -215M USD -50.5%
Stockholders' Equity Attributable to Parent 67.5M USD -17.1%
Liabilities and Equity 82.1M USD -13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.8M USD -27.6%
Net Cash Provided by (Used in) Financing Activities 466K USD +16.8%
Net Cash Provided by (Used in) Investing Activities 3.52M USD -73.8%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 36.4M shares +36.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.9M USD -445%
Deferred Tax Assets, Valuation Allowance 54.1M USD +139%
Deferred Tax Assets, Gross 54.2M USD +138%
Operating Lease, Liability 456K USD +46.2%
Depreciation 22M USD +46.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -72M USD -0.96%
Lessee, Operating Lease, Liability, to be Paid 477K USD +39.5%
Property, Plant and Equipment, Gross 1.05M USD +228%
Operating Lease, Liability, Current 456K USD +180%
Lessee, Operating Lease, Liability, to be Paid, Year Two 129K USD -24.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 358K USD +109%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21K USD -30%
Deferred Tax Assets, Operating Loss Carryforwards 29.2M USD +71.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 4.02M USD +179%
Operating Lease, Payments 237K USD +43.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 75K USD -7.41%
Share-based Payment Arrangement, Expense 4.9M USD +0.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares